Search Results - "Massimo Cristofanilli"

The Landscape of Targeted Therapies in TNBC by Vagia, Elena, Mahalingam, Devalingam, Cristofanilli, Massimo

“…Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype among breast tumors. Despite progress on the underlying tumor biology,…”
Get full text

Molecular characterization and targeted therapeutic approaches in breast cancer by Toss, Angela, Cristofanilli, Massimo

“…Despite the wide improvements in breast cancer (BC) detection and adjuvant treatment, BC is still responsible for approximately 40,000 deaths annually in the…”
Get full text

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer by Turner, Nicholas C, Ro, Jungsil, André, Fabrice, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, Huang Bartlett, Cynthia, Zhang, Ke, Giorgetti, Carla, Randolph, Sophia, Koehler, Maria, Cristofanilli, Massimo

“…In women with hormone-receptor–positive metastatic breast cancer that had progressed after endocrine therapy, palbociclib plus fulvestrant was associated with…”
Get full text

ICAM1 initiates CTC cluster formation and trans-endothelial migration in lung metastasis of breast cancer by Taftaf, Rokana, Liu, Xia, Singh, Salendra, Jia, Yuzhi, Dashzeveg, Nurmaa K., Hoffmann, Andrew D., El-Shennawy, Lamiaa, Ramos, Erika K., Adorno-Cruz, Valery, Schuster, Emma J., Scholten, David, Patel, Dhwani, Zhang, Youbin, Davis, Andrew A., Reduzzi, Carolina, Cao, Yue, D’Amico, Paolo, Shen, Yang, Cristofanilli, Massimo, Muller, William A., Varadan, Vinay, Liu, Huiping

“…Circulating tumor cell (CTC) clusters mediate metastasis at a higher efficiency and are associated with lower overall survival in breast cancer compared to…”
Get full text

Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize by Giuliano, Mario, Shaikh, Anum, Lo, Hin Ching, Arpino, Grazia, De Placido, Sabino, Zhang, Xiang H, Cristofanilli, Massimo, Schiff, Rachel, Trivedi, Meghana V

“…Circulating tumor cell (CTC) clusters may represent one of the key mechanisms initiating the metastasis process. However, the series of pathophysiologic events…”
Get full text

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer by Chae, Young Kwang, Davis, Andrew A, Jain, Sarika, Santa-Maria, Cesar, Flaum, Lisa, Beaubier, Nike, Platanias, Leonidas C, Gradishar, William, Giles, Francis J, Cristofanilli, Massimo

“…While identifying genomic alterations in tumor tissue is the current gold-standard technique for molecular profiling, circulating tumor DNA (ctDNA) represents…”
Get full text

Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer by Schott, Anne F, Goldstein, Lori J, Cristofanilli, Massimo, Ruffini, Pier Adelchi, McCanna, Susan, Reuben, James M, Perez, Raymond P, Kato, Giraldo, Wicha, Max

“…Chemokine receptor 1 (CXCR1) is recognized as an actionable receptor selectively expressed by breast cancer stem cells (BCSCs). Reparixin is an investigational…”
Get full text

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer by Turner, Nicholas C, Slamon, Dennis J, Ro, Jungsil, Bondarenko, Igor, Im, Seock-Ah, Masuda, Norikazu, Colleoni, Marco, DeMichele, Angela, Loi, Sherene, Verma, Sunil, Iwata, Hiroji, Harbeck, Nadia, Loibl, Sibylle, André, Fabrice, Puyana Theall, Kathy, Huang, Xin, Giorgetti, Carla, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…The addition of palbociclib to fulvestrant prolonged overall survival among women with hormone receptor–positive, HER2-negative advanced breast cancer who had…”
Get full text

The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial by O'Leary, Ben, Cutts, Rosalind J, Liu, Yuan, Hrebien, Sarah, Huang, Xin, Fenwick, Kerry, André, Fabrice, Loibl, Sibylle, Loi, Sherene, Garcia-Murillas, Isaac, Cristofanilli, Massimo, Huang Bartlett, Cynthia, Turner, Nicholas C

“…CDK4/6 inhibition with endocrine therapy is now a standard of care for advanced estrogen receptor-positive breast cancer. Mechanisms of CDK4/6 inhibitor…”
Get more information

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer by O’Leary, Ben, Hrebien, Sarah, Morden, James P., Beaney, Matthew, Fribbens, Charlotte, Huang, Xin, Liu, Yuan, Bartlett, Cynthia Huang, Koehler, Maria, Cristofanilli, Massimo, Garcia-Murillas, Isaac, Bliss, Judith M., Turner, Nicholas C.

“…CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are…”
Get full text

Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer by Rossi, Giovanna, Mu, Zhaomei, Rademaker, Alfred W, Austin, Laura K, Strickland, Kimberly S, Costa, Ricardo Lima Barros, Nagy, Rebecca J, Zagonel, Vittorina, Taxter, Timothy J, Behdad, Amir, Wehbe, Firas H, Platanias, Leonidas C, Gradishar, William J, Cristofanilli, Massimo

“…Liquid biopsy provides a real-time assessment of metastatic breast cancer (MBC). We evaluated the utility of combining circulating tumor cells (CTC) and…”
Get full text

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer by Turner, Nicholas C, Liu, Yuan, Zhu, Zhou, Loi, Sherene, Colleoni, Marco, Loibl, Sibylle, DeMichele, Angela, Harbeck, Nadia, André, Fabrice, Bayar, Mohamed Amine, Michiels, Stefan, Zhang, Zhe, Giorgetti, Carla, Arnedos, Monica, Huang Bartlett, Cynthia, Cristofanilli, Massimo

“…A large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to fulvestrant. The…”
Get full text

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer by Fribbens, Charlotte, O'Leary, Ben, Kilburn, Lucy, Hrebien, Sarah, Garcia-Murillas, Isaac, Beaney, Matthew, Cristofanilli, Massimo, Andre, Fabrice, Loi, Sherene, Loibl, Sibylle, Jiang, John, Bartlett, Cynthia Huang, Koehler, Maria, Dowsett, Mitch, Bliss, Judith M, Johnston, Stephen R D, Turner, Nicholas C

“…ESR1 mutations are selected by prior aromatase inhibitor (AI) therapy in advanced breast cancer. We assessed the impact of ESR1 mutations on sensitivity to…”
Get full text

New Treatment Strategies for the Inflammatory Breast Cancer by Vagia, Elena, Cristofanilli, Massimo

“…Opinion statement Inflammatory breast cancer (IBC) remains the most aggressive type of breast cancer. During the past decade, enormous progress has been made…”
Get full text

CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion by Jiao, Xuanmao, Velasco-Velázquez, Marco A, Wang, Min, Li, Zhiping, Rui, Hallgeir, Peck, Amy R, Korkola, James E, Chen, Xuelian, Xu, Shaohua, DuHadaway, James B, Guerrero-Rodriguez, Sandra, Addya, Sankar, Sicoli, Daniela, Mu, Zhaomei, Zhang, Gang, Stucky, Andres, Zhang, Xi, Cristofanilli, Massimo, Fatatis, Alessandro, Gray, Joe W, Zhong, Jiang F, Prendergast, George C, Pestell, Richard G

“…The functional significance of the chemokine receptor CCR5 in human breast cancer epithelial cells is poorly understood. Here, we report that CCR5 expression…”
Get full text

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial by Cristofanilli, Massimo, Prof, Turner, Nicholas C, MD, Bondarenko, Igor, Prof, Ro, Jungsil, MD, Im, Seock-Ah, MD, Masuda, Norikazu, MD, Colleoni, Marco, MD, DeMichele, Angela, MD, Loi, Sherene, MD, Verma, Sunil, MD, Iwata, Hiroji, MD, Harbeck, Nadia, Prof, Zhang, Ke, PhD, Theall, Kathy Puyana, MD, Jiang, Yuqiu, PhD, Bartlett, Cynthia Huang, MD, Koehler, Maria, MD, Slamon, Dennis, Prof

“…Summary Background In the PALOMA-3 study, the combination of the CDK4 and CDK6 inhibitor palbociclib and fulvestrant was associated with significant…”
Get full text

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application by Chae, Young Kwang, Ranganath, Keerthi, Hammerman, Peter S, Vaklavas, Christos, Mohindra, Nisha, Kalyan, Aparna, Matsangou, Maria, Costa, Ricardo, Carneiro, Benedito, Villaflor, Victoria M, Cristofanilli, Massimo, Giles, Francis J

“…The fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) is a tyrosine kinase signaling pathway that has a fundamental role in many biologic…”
Get full text

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice by DeMichele, Angela, Cristofanilli, Massimo, Brufsky, Adam, Liu, Xianchen, Mardekian, Jack, McRoy, Lynn, Layman, Rachel M, Emir, Birol, Torres, Mylin A, Rugo, Hope S, Finn, Richard S

“…Findings from randomized clinical trials may have limited generalizability to patients treated in routine clinical practice. This study examined the…”
Get full text

Molecular mechanisms of metastasis in breast cancer-clinical applications by Cristofanilli, Massimo, Mego, Michal, Mani, Sendurai A

“…Circulating tumor cells (CTCs) have a crucial role in the metastatic cascade, tumor dissemination and progression. Furthermore, CTCs are involved in treatment…”
Get full text

Homophilic CD44 Interactions Mediate Tumor Cell Aggregation and Polyclonal Metastasis in Patient-Derived Breast Cancer Models by Liu, Xia, Taftaf, Rokana, Kawaguchi, Madoka, Chang, Ya-Fang, Chen, Wenjing, Entenberg, David, Zhang, Youbin, Gerratana, Lorenzo, Huang, Simo, Patel, Dhwani B, Tsui, Elizabeth, Adorno-Cruz, Valery, Chirieleison, Steven M, Cao, Yue, Harney, Allison S, Patel, Shivani, Patsialou, Antonia, Shen, Yang, Avril, Stefanie, Gilmore, Hannah L, Lathia, Justin D, Abbott, Derek W, Cristofanilli, Massimo, Condeelis, John S, Liu, Huiping

“…Circulating tumor cells (CTC) seed cancer metastases; however, the underlying cellular and molecular mechanisms remain unclear. CTC clusters were less…”
Get more information